NASDAQ:SCNI Scinai Immunotherapeutics Q4 2025 Earnings Report $1.55 -0.31 (-16.67%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.57 +0.02 (+1.35%) As of 09/25/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Scinai Immunotherapeutics EPS ResultsActual EPS$38.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AScinai Immunotherapeutics Revenue ResultsActual Revenue$0.27 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AScinai Immunotherapeutics Announcement DetailsQuarterQ4 2025Date4/1/2026TimeAfter Market ClosesConference Call DateWednesday, April 1, 2026Conference Call Time7:00AM ETUpcoming EarningsScinai Immunotherapeutics' Q3 2026 earnings is estimated for Wednesday, December 2, 2026, based on past reporting schedulesConference Call ResourcesPress Release (6-K)Annual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(20-F) Scinai Immunotherapeutics Earnings HeadlinesScinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Short Interest UpdateSeptember 26 at 4:40 AM | americanbankingnews.comSCINAI IMMUNOTHERAPEUTICS LTD: Scinai Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 21, 2026 | finanznachrichten.deThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.September 27 at 1:00 AM | Chaikin Analytics (Ad)Scinai Regains Compliance with Nasdaq Minimum Bid Price RequirementSeptember 21, 2026 | prnewswire.comScinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO BusinessSeptember 8, 2026 | prnewswire.comScinai Immunotherapeutics Ltd. (SCNI) Q2 2026 Earnings Call TranscriptAugust 26, 2026 | seekingalpha.comSee More Scinai Immunotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scinai Immunotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scinai Immunotherapeutics and other key companies, straight to your email. Email Address About Scinai ImmunotherapeuticsScinai Immunotherapeutics (NASDAQ:SCNI) Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing immunotherapies for inflammatory and autoimmune diseases. The company is developing treatments designed to target disease-related immune pathways while potentially providing localized delivery and reduced systemic exposure. Scinai’s development platform is based on NanoAbs, or nanobodies, which are small antibody-derived molecules intended to bind selectively to therapeutic targets. Its lead program is an anti-IL-17 NanoAb candidate being developed for topical treatment of psoriasis and potentially other inflammatory conditions. The company is also evaluating additional applications for its platform across immune-mediated diseases. Scinai serves the biopharmaceutical market through research and development of its proprietary therapeutic candidates and technology platform. The company is headquartered in Israel and is conducting its work as a development-stage biotechnology business; product candidates remain subject to clinical testing and regulatory review before they can be marketed.View Scinai Immunotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
